OncoKB New Data Release - February 8, 2024
Contact OncoKB
Data Release v4.14
February 8, 2024
What's New
Updated Therapeutic Implications:
New alteration(s) with a tumor type-specific level of evidence
Level 3A: Milademetan added as a treatment for MDM2 Amplification in intimal sarcoma based on clinical trial data (PMID: 37369013)
Removal of therapie(s) and changed tumor type-specific level of evidence for an alteration(s)
No Level: Erdafitinib removed as a treatment for FGFR2 Fusions in bladder cancer (previously Level 1) based on amendment to the FDA-drug label for erdafitinib and the lack of clinical response in the BLC2001 trial (PMID: 31340094)
Demotion of tumor type-specific level of evidence for an alteration(s)
Level 2: FGFR3 Fusions (excluding FGFR3-TACC3 Fusion, FGFR3-BAIAP2L1 Fusion which remain Level 1) in bladder cancer demoted from Level 1 to Level 2 based on adherence to the FDA-drug label for erdafitinib and inclusion of erdafitinib as a treatment recommendation for patients with “susceptible FGFR3 alterations” in the NCCN Bladder Cancer Guidelines V3.2023 (PMID: 37870920)
Promotion of tumor type-specific level of evidence for an alteration(s)
Level 2: FGFR3 S371C, G380R, K650 in bladder cancer promoted from Level 3A to Level 2 based on adherence to the FDA-drug label for erdafitinib and inclusion of erdafitinib as a treatment recommendation for patients with “susceptible FGFR3 alterations” in the NCCN Bladder Cancer Guidelines V3.2023 (PMID: 37870920)
Level 2: FGFR3 Oncogenic Mutations (excluding G370C, R248C, S249C, Y373C which remain Level 1) in bladder cancer promoted from Level 4 to Level 2 based on adherence to the FDA-drug label for erdafitinib and inclusion of erdafitinib as a treatment recommendation for patients with “susceptible FGFR3 alterations” in the NCCN Bladder Cancer Guidelines V3.2023 (PMID: 37870920)
Level 3A: MDM2 Amplification in dedifferentiated liposarcoma and well-differentiated liposarcoma promoted from Level 4 to Level 3A based on clinical trial data for brigimadlin (PMID: 37269344)
Drug(s) currently in OncoKB™: Milademetan (Level 4)
Gene Curation:
Addition of 14 new genes:
ANKRD26 ARHGAP26 ATIC CD70 ERCC1 FGF1 FGF2 FGF5 HFE HOXA11 MN1 PML SRP72 TNFRSF17
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
